Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: An apparatus is provided. The apparatus may include one or more of a container, a first magnet assembly, and a second magnet assembly. The container includes an open top and is configured to hold a liquid chemical solution. The first magnet assembly includes a first magnet having a first polarity and a cover, coupled to the first magnet. The cover is configured to be movable between an open and a closed position and limit evaporation of the solution when the cover is in the closed position. The second magnet assembly includes a second magnet having a second polarity. In response to a command, the second magnet assembly is configured to move the cover to the open position without direct contact to the first magnet assembly in response to a command.

Abstract: A device is provided. The device may include one or more of a package base, a substrate, a die secured to the substrate, a plurality of bond connections, and a package lid. The package base includes a plurality of package leads and a package base body. The package base body includes an open cavity disposed through the entire package base body, a plurality of package bond pads, disposed within a periphery of the open cavity, and a mounting shelf, disposed within the open cavity. The substrate is secured to the mounting shelf, and includes a plurality of substrate bond pads. The plurality of bond connections are configured to provide electrical connections between one or more of the die, the substrate bond pads, and the package bond pads. The package lid is secured over the open cavity to the package base body.

Abstract: A device is provided. The device may include one or more of a package base, a substrate, a die secured to the substrate, a plurality of bond connections, and a package lid. The package base includes a plurality of package leads and a package base body. The package base body includes an open cavity disposed through the entire package base body, a plurality of package bond pads, disposed within a periphery of the open cavity, and a mounting shelf, disposed within the open cavity. The substrate is secured to the mounting shelf, and includes a plurality of substrate bond pads. The plurality of bond connections are configured to provide electrical connections between one or more of the die, the substrate bond pads, and the package bond pads. The package lid is secured over the open cavity to the package base body.

Abstract: An apparatus is provided. The apparatus may include one or more of a container, a first magnet assembly, and a second magnet assembly. The container includes an open top and is configured to hold a liquid chemical solution. The first magnet assembly includes a first magnet having a first polarity and a cover, coupled to the first magnet. The cover is configured to be movable between an open and a closed position and limit evaporation of the solution when the cover is in the closed position. The second magnet assembly includes a second magnet having a second polarity. In response to a command, the second magnet assembly is configured to move the cover to the open position without direct contact to the first magnet assembly in response to a command.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: Methods of treating eyelid swelling in a subject comprising administering to the ocular surface of the subject an effective amount of glycerol and naphazoline. The glycerol can be present at a concentration of about 7.5% w/v and the naphazoline can be present at a concentration of about 0.01% to about 0.5% w/v. The compositions do not comprise an antihistamine.

Abstract: A screen basket for centrifuges having a wedge wire with a broad end and an opposite narrow end. The wedge wire narrows in width from the broad end to the narrow end and the wedge wire increases in depth from the broad end to the narrow end.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The invention relates to novel bioactive polycyclic ether compounds comprising a spiro-linked five-membered cyclic imine. In particular, the invention relates to a compound designated portimine, its congeners and the use of these compounds in anticancer therapy. In a second aspect the invention provides a pharmaceutical preparation comprising as active ingredient a congener of the first aspect of the invention. Preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with neoplasia. More preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with lymphoid malignancies. Preferably, the lymphoid malignancies are selected from the group consisting of: chronic lymphocytic leukaemia (CLL) and pediatric acute lymphoblastic leukaemia (ALL).

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Abstract: The invention relates to novel bioactive polycyclic ether compounds comprising a spiro-linked five-membered cyclic imine. In particular, the invention relates to a compound designated portimine, its congeners and the use of these compounds in anticancer therapy. In a second aspect the invention provides a pharmaceutical preparation comprising as active ingredient a congener of the first aspect of the invention. Preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with neoplasia. More preferably, the pharmaceutical preparation is indicated for use in the treatment of subjects with lymphoid malignancies. Preferably, the lymphoid malignancies are selected from the group consisting of: chronic lymphocytic leukaemia (CLL) and pediatric acute lymphoblastic leukaemia (ALL).

Abstract: A ticket validation device that is protected from debris ingression includes a validator housing defining a ticket entry bezel. The ticket entry bezel defines a first and second major sides and shorter connecting regions that connect the two major sides. The device includes an acceptor assembly that transports a ticket to a ticket reader device and at least one flap positioned between the acceptor assembly and the ticket entry bezel. The flap is biased against one of the first major side or the second major side of the entry bezel. A ticket-side of the flap is pushed away from the one of the major sides by the ticket when inserted into the ticket entry bezel such that the ticket scrapes between a distal end of the flap and the one of the major sides to remove any loose debris from the ticket prior to the ticket reaching the acceptor assembly.

Abstract: A screen basket for centrifuges having a wedge wire with a broad end and an opposite narrow end. The wedge wire narrows in width from the broad end to the narrow end and the wedge wire increases in depth from the broad end to the narrow end.

Abstract: Congener of portimine of the structure: where: R1 is selected from H, acyl, alkyl, alkylene, aryl and aralkyl; R2 is selected from H, acyl, alkyl, alkylene, aryl and aralkyl; M is O, S, N—NH2, N(alkyl)2, N-alkoxy or N(aryl)2; W and X may form a bond, an epoxide, or are independently selected from H, halogen, OH and O-acyl. Y and Z form a bond, an epoxide, or are independently selected from H, halogen (X), OH and O-acyl; and R1 and R2 are not H, M is not O, or W and X or Y and Z do not form a bond.

Abstract: As may be implemented in a manner consistent with one or more embodiment, aspects of the disclosure are directed to latency control with signals, such as audio signals. For instance, a quality characteristic of an audio signal having time-sequenced frames exhibiting a signal quality can assessed, and an output indicative of the signal quality is provided based on the assessment. An amount of latency in the audio signal is dynamically adjusted based on the output, and the latency can be used in processing the time-sequenced frames, such as to use future frames in assessing or correcting a current frame during a time period facilitated via the latency.